EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition

by Elena Iemma | Nov 4, 2021 | News

PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...

Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax

by Elena Iemma | Jul 6, 2021 | News

PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...

EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

by Elena Iemma | Apr 27, 2021 | News

PROVIDENCE, RI, April 27, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs” in Frontiers in Immunology. This research highlights Tregitopes as a promising...

AAPS BPABC Community Presentation: In silico Immunogenicity Prediction for Protein and Peptide Therapeutics

by Elena Iemma | Mar 11, 2021 | Events, Webinars

Aimee Mattei, Senior Project Manager on our Bioinformatics team, will be presenting to the AAPS BPABC(biopharmaceutical product attributes and biological consequences) Community on March 18th at 12pm ET. You’ll need to join the group to register, membership is...

FDA Webinar: Non-clinical Immunogenicity Assessment of Generic Peptide Products: Development, Validation, and Sampling

by Elena Iemma | Jan 26, 2021 | Events, Webinars

The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...